382 related articles for article (PubMed ID: 25014023)
21. Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment.
Lin MS; Liao PY; Chen HM; Chang CP; Chen SK; Chern Y
J Neurosci; 2019 Feb; 39(8):1505-1524. PubMed ID: 30587542
[TBL] [Abstract][Full Text] [Related]
22. Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease.
Klevytska AM; Tebbenkamp AT; Savonenko AV; Borchelt DR
J Neuropathol Exp Neurol; 2010 Apr; 69(4):396-404. PubMed ID: 20448484
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
[TBL] [Abstract][Full Text] [Related]
24. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
25. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model.
Cheng Y; Peng Q; Hou Z; Aggarwal M; Zhang J; Mori S; Ross CA; Duan W
Neuroimage; 2011 Jun; 56(3):1027-34. PubMed ID: 21320608
[TBL] [Abstract][Full Text] [Related]
26. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
27. High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice.
Molnár MF; Török R; Szalárdy L; Sümegi E; Vécsei L; Klivényi P
Acta Neurobiol Exp (Wars); 2016; 76(3):176-81. PubMed ID: 27685770
[TBL] [Abstract][Full Text] [Related]
28. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.
Schilling G; Savonenko AV; Klevytska A; Morton JL; Tucker SM; Poirier M; Gale A; Chan N; Gonzales V; Slunt HH; Coonfield ML; Jenkins NA; Copeland NG; Ross CA; Borchelt DR
Hum Mol Genet; 2004 Aug; 13(15):1599-610. PubMed ID: 15190011
[TBL] [Abstract][Full Text] [Related]
29. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
30. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of copper ion mediated Huntington's disease progression.
Fox JH; Kama JA; Lieberman G; Chopra R; Dorsey K; Chopra V; Volitakis I; Cherny RA; Bush AI; Hersch S
PLoS One; 2007 Mar; 2(3):e334. PubMed ID: 17396163
[TBL] [Abstract][Full Text] [Related]
32. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.
Dorner JL; Miller BR; Barton SJ; Brock TJ; Rebec GV
Behav Brain Res; 2007 Mar; 178(1):90-7. PubMed ID: 17239451
[TBL] [Abstract][Full Text] [Related]
33. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
Kenney C; Powell S; Jankovic J
Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
[TBL] [Abstract][Full Text] [Related]
34. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
[TBL] [Abstract][Full Text] [Related]
35. Viral vector mediated expression of mutant huntingtin in the dorsal raphe produces disease-related neuropathology but not depressive-like behaviors in wildtype mice.
Pitzer M; Lueras J; Warden A; Weber S; McBride J
Brain Res; 2015 May; 1608():177-90. PubMed ID: 25732261
[TBL] [Abstract][Full Text] [Related]
36. Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
Donley DW; Realing M; Gigley JP; Fox JH
PLoS One; 2021; 16(5):e0250606. PubMed ID: 33989290
[TBL] [Abstract][Full Text] [Related]
37. Experimental mutagenesis of huntingtin to map cleavage sites: different outcomes in cell and mouse models.
Tebbenkamp AT; Xu G; Siemienski ZB; Janus C; Fromholt SE; Brown HH; Swing D; Tessarollo L; Borchelt DR
J Huntingtons Dis; 2014; 3(1):73-86. PubMed ID: 25062766
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
Ebert AD; Barber AE; Heins BM; Svendsen CN
Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
[TBL] [Abstract][Full Text] [Related]
39. Nuclear translocation of STAT5 initiates iron overload in huntington's disease by up-regulating IRP1 expression.
Niu L; Zhou Y; Wang J; Zeng W
Metab Brain Dis; 2024 Apr; 39(4):559-567. PubMed ID: 38261161
[TBL] [Abstract][Full Text] [Related]
40. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
